Gene therapy of focal-onset epilepsy by adeno-associated virus vector-mediated overexpression of neuropeptide y

Francesco M. Noe', Andreas T. Sãrensen, Merab Kokaia, Annamaria Vezzani

Research output: Contribution to journalArticlepeer-review

Abstract

Adeno-associated virus (AAV)-mediated neuropeptide Y (NPY) overexpression in areas of seizure onset or generalization may be effective for the treatment of pharmacoresistant seizures in focal onset epilepsy. NPY overexpression mediates anticonvulsant activity in various seizures models and antiepileptogenic effects in kindling. Side effects are limited thus suggesting that this therapeutic approach could be effective and relatively safe. For an expanded treatment of this topic see Jasper's basic mechanisms of the epilepsies. 4th ed. (Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, eds) published by Oxford University Press (available on the National Library of Medicine Bookshelf [NCBI] at).

Original languageEnglish
Pages (from-to)96
Number of pages1
JournalEpilepsia
Volume51
Issue numberSUPPL. 5
DOIs
Publication statusPublished - Dec 2010

Keywords

  • Gene overexpression
  • Kainic acid
  • Kindling
  • Pharmacoresistant seizures
  • Viral vector

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint

Dive into the research topics of 'Gene therapy of focal-onset epilepsy by adeno-associated virus vector-mediated overexpression of neuropeptide y'. Together they form a unique fingerprint.

Cite this